Patents Assigned to AstraZeneca
  • PHARMACEUTICAL FORMULATION USE 030
    Publication number: 20090061000
    Abstract: An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)—(R)CH(OH)C(O)—(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes.
    Type: Application
    Filed: August 28, 2008
    Publication date: March 5, 2009
    Applicant: AstraZeneca AB
    Inventors: Bertil Sven Inge Abrahamsson, Susanna Johanna Abrahmsen Alami, Hakan Lars Bagger-Jorgensen, Marie Christine Sindeby Cullberg, Lars Johan Pontus de Verdier Hjartstam, Susanne Anette Nilsson
  • Enantiomers of selected fused heterocyclics and uses thereof
    Patent number: 7498333
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: March 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Compounds
    Patent number: 7498338
    Abstract: The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, t, R3, R4, R5, R6, R7 and R8 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: March 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Nafizal Hossain, Svetlana Ivanova, Marguerite Mensonides-Harsema, Austen Pimm, James Reuberson
  • Oxazolidinones as antibacterial agents
    Patent number: 7498350
    Abstract: A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: Wherein C is selected from (D) and (E), R2a, R6a, and R3a are independently selected from for example H, CF3, Me and Et; R2b and R6b are independently selected from for example H, F, CF3, Me and Et; R1b is for example optionally substituted diazolyl, triazolyl or tetrazolyl; R4 is for example an optionally substituted 5- or 6-membered heterocyclic ring system. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: March 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Michael Barry Gravestock, Neil James Hales, Folkert Reck, Fei Zhou
  • Method of producing an antiangiogenic or vascular permeability reducing effect
    Patent number: 7498335
    Abstract: The invention concerns the use of a quinazoline derivative of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X1 includes a direct bond and O and Q3includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R2 and R3 is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.
    Type: Grant
    Filed: March 1, 2001
    Date of Patent: March 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Laurent Francois Andre Hennequin, Graham Charles Crawley, Darren McKerrecher, Patrick Ple, Jeffrey Philip Poyser, Christine Marie Paul Lambert
  • QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS
    Publication number: 20090054469
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 28, 2005
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Paul Lyne, Timothy Pontz
  • SUBSTITUTED THIOPHENES AND USES THEREOF
    Publication number: 20090054396
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: September 8, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Mei Su, Dingwei Yu, Stephanie Springer
  • Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
    Publication number: 20090054413
    Abstract: The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a PDE 4 mediated disease state.
    Type: Application
    Filed: October 2, 2006
    Publication date: February 26, 2009
    Applicant: AstraZeneca AB
    Inventors: Krister Henriksson, Annea Lisius, Peter Sjo, Peter Storm
  • New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias
    Publication number: 20090054422
    Abstract: There is provided compounds of formula I, wherein R1, R2, R3, R41 to R46, X, Y and Z have meanings given in the description, which compounds are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: June 12, 2006
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Annika Bjore, David Cladingboel, Gareth Ensor, Adam Herring, Johan Kajanus, Robert Lundqvist, Christina Olsson, Carl-Gustav Sigfridsson, Gert Strandlund
  • Process to Prepare Sulfonyl Chloride Derivatives
    Publication number: 20090054659
    Abstract: A novel process for the preparation of hydantoin sulfonyl chlorides of general formula (I) wherein R and n are as specified in the description, and certain novel intermediates thereto, are disclosed.
    Type: Application
    Filed: March 15, 2007
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Philip Cornwall, Daniel Horner
  • 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS
    Publication number: 20090054411
    Abstract: The invention relates to chemical compounds of formula IA or IB: or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: October 13, 2008
    Publication date: February 26, 2009
    Applicant: AstraZeneca AB
    Inventors: Donald Cook, Leslie Dakin, David Del Valle, Thomas Gero, David Scott, Xiaolan Zheng
  • Amide Substituted Quinolines
    Publication number: 20090054445
    Abstract: Compounds of Formula I wherein R1, A, R2, n, R3, m, R4, R5 and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: January 25, 2007
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey Albert, Cristobal Alhambra, James Kang, Gerard Koether, Yan Li, Thomas Simpson, James Woods
  • NOVEL PYRIMIDINE DERIVATIVES 965
    Publication number: 20090054428
    Abstract: The invention concerns compounds of Formula I, or a pharmaceutically acceptable salt thereof, where R1, Q, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4 kinases.
    Type: Application
    Filed: July 17, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Richard Ducray
  • New Combination 937
    Publication number: 20090053176
    Abstract: The present invention related to a combination of (a) a compound which is a MPO inhibitor or a pharmaceutically acceptable salt thereof and (b) a compound or a pharmaceutically acceptable salt thereof, which is used in the treatment and/or prevention of PD or Multiple Sclerosis. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating Neuroinflammatory and Neurodegenerative Disorder(s), such as PD and Multiple Sclerosis in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of Neuroinflammatory Disorder(s).
    Type: Application
    Filed: August 21, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Gabrielle Ahlberg, Hakan Eriksson
  • Use
    Publication number: 20090054491
    Abstract: The present invention relates to the use of compounds of formula II for the treatment or prevention of obesity.
    Type: Application
    Filed: June 19, 2006
    Publication date: February 26, 2009
    Applicant: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Abdelmalik Slassi, Mats Nagard, Leonard Storlien, David Morgan
  • New Use 938
    Publication number: 20090054468
    Abstract: The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.
    Type: Application
    Filed: August 21, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Hakan Eriksson, Werner Poewe
  • CHEMICAL COMPOUNDS
    Publication number: 20090054398
    Abstract: The invention provides a new method for treating disorders associated with activation of the Notch signal transduction pathway comprising administering an effective amount of a compound of Formula (I), in free form or in a pharmaceutically acceptable salt form or in the form of a pharmaceutically acceptable solvate of the compound or the salt, to a human or animal patient in need thereof.
    Type: Application
    Filed: March 9, 2007
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Hudson, Naomi Laing, Paula Lewis
  • System and Method for Cultivating Cells
    Publication number: 20090053810
    Abstract: The invention relates to a method of introducing a substance into a multi-layered cell factory. A substance is poured into a substance transferring device e.g. a funnel and a tube connected to the cell factory, which directly transfers the substance into the cell factory arranged with its layers extending substantially vertically. The invention also relates to a cell-cultivation system.
    Type: Application
    Filed: April 10, 2006
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Laura Sander, Annika Sundberg
  • Chemical compounds
    Patent number: 7495013
    Abstract: The present invention relates to compounds of formula (I): The variables recited in formula (I) are defined in the specification. The present invention also relates to processes of preparing compounds of formula (I) and uses of such compounds for treating a chemokine (e.g., CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: February 24, 2009
    Assignee: AstraZeneca AB
    Inventors: Moya Caffrey, Christopher Luckhurst, Tobias Mochel, Matthew Perry, Brian Springthorpe
  • CHEMICAL COMPOUNDS-821
    Publication number: 20090048269
    Abstract: The invention relates to chemical compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess ALK5 (TGF?R1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: August 12, 2008
    Publication date: February 19, 2009
    Applicant: AstraZeneca AB
    Inventors: Maurice Raymond Finlay, Frederick Woolf Goldberg, Craig Anthony Roberts, Nicola Jane Roberts, David Alan Rudge